Exciting Advances in Cancer Treatment Shared at 2025 ASCO Annual Meeting

Groundbreaking Updates in Cancer Therapy at the 2025 ASCO Annual Meeting

The 2025 ASCO Annual Meeting, a pivotal event in oncology, was held in Chicago from May 30 to June 3, showcasing innovative research and advancements in cancer treatment. Among the highlights, Duality Bio (HKEX: 9606.HK) presented preliminary data from two noteworthy clinical trials for their antibody-drug conjugate (ADC) candidates, DB-1310 and DB-1311/BNT324, demonstrating significant promise in treating advanced cancers.

Overview of Clinical Trials Presented

During this year's oral sessions, Dr. Andrew Parsonson and Professor Aaron E. Lisberg provided insights into the dual focus of their research: the efficacy of the HER3-targeting ADC, DB-1310, and the B7H3-targeting ADC, DB-1311/BNT324, which is being developed alongside BioNTech.

DB-1311/BNT324 Clinical Trial Results

The detailed presentation on B7H3 ADC candidate DB-1311/BNT324 focused on its application for patients suffering from heavily pre-treated castration-resistant prostate cancer (CRPC). Early data exhibited a confirmed objective response rate (cORR) of 30.8%, along with a robust disease control rate (DCR) of 90.4% among 52 patients evaluated. Notably, the 6-month radiographic progression-free survival (rPFS) rate stood at 69.8%, suggesting a favorable response to this treatment. With gastrointestinal and hematologic adverse events cited as the primary side effects, the trial showcased a manageable safety profile, urging the ongoing enrollment of patients into various cohorts, including those with taxane-naïve CRPC.

DB-1310 Findings

The findings from the first-in-human Phase I/IIa study of DB-1310 indicated dramatic results, particularly amongst patients with EGFR-mutated non-small cell lung cancer (NSCLC), where the unconfirmed objective response rate reached an impressive 44%. The overall disease control rate was 84%, with median progression-free survival lasting about 7.0 months and median overall survival reaching 18.9 months. The tolerability of the drug was confirmed as favorable, with most adverse events being categorized as Grade 1-2, translating into a low discontinuation rate of 3.5%.

These results fuel optimism for the continued development of DB-1310, especially its potential for both monotherapy and combinatorial approaches with other cancer treatments, thereby expanding the arsenal available to oncologists worldwide.

The Importance of These Developments

The rising incidence of prostate cancer underlines an urgent need for new therapies aimed at this often-relentless form of the disease. The positive results of the clinical trials underscore ongoing commitments to innovation in cancer therapy, particularly for patients with limited treatment options. Duality Bio’s advancements are stepping stones toward addressing these unmet clinical needs.

As a major participant in the emerging ADC field, Duality Biotherapeutics is strategically positioning itself to lead in the development of targeted therapies against various cancers. With existing collaborations and a robust pipeline, the company is well on its way to launching impactful treatments that could reshape cancer care.

For anyone interested in the latest treatments for cancer, Duality Bio's developments herald an exciting phase of progress, reinforcing the need for relentless research and investment in groundbreaking oncology solutions.

For more detailed information about Duality Bio and their innovations, please visit Duality Bio’s website.